LOXO BTK20020 (BRUIN CLL-321): A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator’s Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL321)

Professor David Allsup D.J.Allsup@hull.ac.uk
Professor of Haematology

LIPS: A prospective registry-based cohort study to monitor the diagnosis and management of acute leukaemia in pregnancy Jun 1, 2018 - Feb 28, 2022
Acute leukaemia (AL) is an aggressive but potentially curable cancer that can affect women of childbearing age. When a pregnancy is complicated by a diagnosis of AL, clinicians face a complex dilemma: to balance risking the mother’s survival through... Read More about LIPS: A prospective registry-based cohort study to monitor the diagnosis and management of acute leukaemia in pregnancy.

CLL Research Jan 26, 2015 - Dec 31, 2028
Translational research project utilising prospective sample collection from patients attending the Haematology Clinic, Hull university Teaching Hospital Trust, to facilitate research within the University of Hull.

STATIC: A Randomised Phase III Trial Comparing Continuous with Intermittent Treatment Strategies in Chronic Lymphocytic Leukaemia (CLL) Jan 1, 2021 - Mar 31, 2031
Chronic lymphocytic leukaemia (CLL) is a cancer that affects the blood and bone marrow. It tends to progress slowly, and is incurable. CLL is the most common leukaemia in adults. The first treatment for CLL is chemotherapy. This is usually given for... Read More about STATIC: A Randomised Phase III Trial Comparing Continuous with Intermittent Treatment Strategies in Chronic Lymphocytic Leukaemia (CLL).

Matrix Metalloproteinase Activated Multimodal 'Theranostic' Drug Delivery Imaging Agents For Thrombosis Mar 1, 2020 - Aug 31, 2024

B-More: A 24-month prospective, non-interventional, international, multicentre study to describe the real-world effectiveness and usage of Alprolix in patients with haemophilia B in selected European and Middle Eastern countries Sep 1, 2019 - Dec 31, 2022
A phase IV multicentre, international study investigating the real-world efficacy of Alprolix, an extended half-life factor IX concentrate, in the management of haemophilia B.